We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+4.05%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$6.32B
AUM Growth
+$456M
(+7.8%)
Cap. Flow
+$224M
Cap. Flow
% of AUM
3.55%
Top 10 Holdings %
Top 10 Hldgs %
17.62%
Holding
844
New
72
Increased
349
Reduced
257
Closed
60
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$37.6M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$29.3M |
| 3 |
Biogen
BIIB
|
+$27.4M |
| 4 |
Home Depot
HD
|
+$22.7M |
| 5 |
Cisco
CSCO
|
+$21.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan Chase
JPM
|
+$23.6M |
| 2 |
TJX Companies
TJX
|
+$19.3M |
| 3 |
FedEx
FDX
|
+$16.4M |
| 4 |
Intuit
INTU
|
+$14.7M |
| 5 |
Corning
GLW
|
+$13.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.18% |
| 2 | Technology | 17.19% |
| 3 | Financials | 12.85% |
| 4 | Consumer Discretionary | 10.2% |
| 5 | Communication Services | 8.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
526
Iovance Biotherapeutics
IOVA
$2.23B
| $1.43M | 0.02% |
112,000
+15,000
| +15% | +$219K |
|
527
Ally Financial
ALLY
$13.1B
| $1.43M | 0.02% |
54,294
+4,426
| +9% | +$118K |
|
528
Pacira BioSciences
PCRX
$1.02B
| $1.42M | 0.02% |
44,440
| – | – |
|
529
Globe Life
GL
$13.5B
| $1.4M | 0.02% |
+17,214
| New | +$1.46M |
|
|
LUMO
530
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $1.4M | 0.02% |
32,556
| – | – |
|
531
Genuine Parts
GPC
$17.1B
| $1.38M | 0.02% |
15,068
+543
| +4% | +$49.5K |
|
532
Markel Group
MKL
$25B
| $1.37M | 0.02% |
1,262
-105
| -8% | -$119K |
|
533
Cintas
CTAS
$82.4B
| $1.36M | 0.02% |
29,472
-2,428
| -8% | -$109K |
|
534
Skyworks Solutions
SWKS
$9.06B
| $1.36M | 0.02% |
14,111
-6,771
| -32% | -$658K |
|
535
Essex Property Trust
ESS
$18.9B
| $1.33M | 0.02% |
5,557
-499
| -8% | -$119K |
|
536
Realty Income
O
$61.2B
| $1.32M | 0.02% |
25,416
| – | – |
|
537
Owens Corning
OC
$11.5B
| $1.32M | 0.02% |
20,873
-1,215
| -6% | -$83.9K |
|
538
Vulcan Materials
VMC
$36.3B
| $1.32M | 0.02% |
10,252
-40,872
| -80% | -$5.04M |
|
539
Mohawk Industries
MHK
$6.9B
| $1.32M | 0.02% |
6,165
+10
| +0.2% | +$2.19K |
|
|
KSU
540
DELISTED
Kansas City Southern
KSU
| $1.32M | 0.02% |
12,444
-9,934
| -44% | -$1.08M |
|
|
MRO
541
DELISTED
Marathon Oil Corporation
MRO
| $1.3M | 0.02% |
62,311
-5,875
| -9% | -$116K |
|
542
Equifax
EFX
$20.3B
| $1.29M | 0.02% |
10,320
-27,538
| -73% | -$3.26M |
|
543
Cheniere Energy
LNG
$56.5B
| $1.27M | 0.02% |
19,429
-1,050
| -5% | -$64.6K |
|
|
FPRX
544
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $1.26M | 0.02% |
80,000
| – | – |
|
545
Macy's
M
$6.15B
| $1.26M | 0.02% |
33,703
-76,560
| -69% | -$2.57M |
|
|
HDS
546
DELISTED
HD Supply Holdings, Inc.
HDS
| $1.26M | 0.02% |
29,364
+3,791
| +15% | +$154K |
|
547
Artivion
AORT
$1.23B
| $1.25M | 0.02% |
45,000
| – | – |
|
548
Wynn Resorts
WYNN
$10.1B
| $1.25M | 0.02% |
7,474
-27,488
| -79% | -$5.07M |
|
|
EGN
549
DELISTED
Energen
EGN
| $1.25M | 0.02% |
+17,151
| New | +$1.12M |
|
550
AngioDynamics
ANGO
$562M
| $1.25M | 0.02% |
56,000
| – | – |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2018 Portfolio in Review
As of Q2 2018, Candriam SCA held 844 positions worth $6.32B, up 7.8% from $5.86B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Candriam SCA deployed $224M of net new capital in Q2 2018, opening 72 new positions and adding to 349 existing holdings. Its largest new stake was Broadcom: 1,532,450 shares worth $37.2M.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 23% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was JPMorgan Chase, an estimated $23.6M trimmed.
- Candriam SCA's largest Q2 2018 buy was Broadcom: 1,532,450 shares worth $37.2M.
- Candriam SCA added most to Bristol-Myers Squibb in Q2 2018, an estimated $29.3M increase.
- Candriam SCA's biggest Q2 2018 reduction was JPMorgan Chase, cutting an estimated $23.6M.
- Candriam SCA fully exited Monsanto Co in Q2 2018, selling an estimated $11.5M.
- Candriam SCA's ten largest holdings make up 18% of its $6.32B portfolio in Q2 2018.
- Candriam SCA opened 72 new positions and closed 60 in Q2 2018.
- Candriam SCA's portfolio value rose 7.8% quarter-over-quarter to $6.32B.
Based on Candriam SCA's 13F filing for Q2 2018, filed 14 Aug 2018.